RecruitingPhase 4
Evaluation of Pain Treatment After Total Knee Arthroplasty
Vertex Pharmaceuticals Incorporated · NCT07538570
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–80 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 4
- Target enrollment
- 60
- US sites recruiting
- 2
- Study start
- April 24, 2026
- Record last updated
- August 18, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).
Being studied: Suzetrigine; Placebo
Conditions: Pain
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Key Inclusion Criteria
- Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
- Scheduled to undergo an elective primary unilateral TKA surgery
Key Exclusion Criteria
- History of previous TKA surgery on incident side
Other protocol defined Inclusion/Exclusion criteria will apply.
Recruiting US locations
Legent Orthopedic and Spine Hospital
Bellaire, TX 77401
Memorial Hermann Village Office
Houston, TX 77043
Study contacts (from the official record)
- Medical Information · 617-341-6777 · medicalinfo@vrtx.com